amphetamine has been researched along with Hyperactivity, Motor in 209 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have shown previously that aberrant hippocampal (HPC) output underlies the dopamine (DA) dysfunction observed in the methylazoxymethanol acetate (MAM) developmental model of schizophrenia in the rodent." | 3.77 | A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. ( Aras, S; Cook, JM; Gill, KM; Grace, AA; Lodge, DJ, 2011) |
| " Following repeated administration of the higher dose of IMI together with AMA, we observed an increase in clonidine-induced aggression in mice, and significant enhancement of D-amphetamine-induced locomotor hyperactivity, as well as phenylephrine-induced exploratory behavior, in rats." | 3.72 | The effect of combined treatment with imipramine and amantadine on the behavioral reactivity of central alpha1-adrenergic system in rats. ( Dziedzicka-Wasylewska, M; Faron-Górecka, A; Rogóz, Z; Solich, J, 2004) |
| "Besides seizures, patients with epilepsy are affected by a variety of cognitive and psychiatric comorbidities that further impair their quality of life." | 1.48 | 6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain. ( Albertini, G; De Bundel, D; Demuyser, T; Massie, A; Smolders, I; Walrave, L, 2018) |
| " We therefore assessed dose-response effects of amphetamine (0." | 1.46 | Effects of amphetamine on pro-social ultrasonic communication in juvenile rats: Implications for mania models. ( Engelhardt, KA; Fuchs, E; Schwarting, RKW; Wöhr, M, 2017) |
| "PWZ-029 did not affect recognition memory deficits in social novelty discrimination procedure." | 1.42 | Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion. ( Biawat, P; Cook, JM; Joksimović, S; Marković, B; Savić, MM; Stanković, T; Timić Stamenić, T, 2015) |
| "Trehalose 1 or 2% was administered for 3 weeks as a drinking solution to Black Swiss mice (a model of manic-like behaviors) or 2% to ICR mice and their behavior evaluated in a number of tests related to depression or mania." | 1.39 | Trehalose induced antidepressant-like effects and autophagy enhancement in mice. ( Agam, G; Anderson, GW; Belmaker, RH; Einat, H; Kara, NZ; Toker, L, 2013) |
| "Elfn1 mutant mice exhibit seizures, subtle motor abnormalities, reduced thigmotaxis and hyperactivity." | 1.39 | Mutation of Elfn1 in mice causes seizures and hyperactivity. ( Dolan, J; Mitchell, KJ, 2013) |
| " The dose-response curves were, however, different for the different behaviors." | 1.37 | Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). ( Sagvolden, T, 2011) |
| " Amphetamine and diazepam produced an inverted U-shaped dose-response effect on different parameters of the test and demonstrate that the drug concentration which elicited a peak in mean number of entries is different from the drug concentration which elicited a peak in mean duration of entries." | 1.36 | Distinguishing anxiolysis and hyperactivity in an open space behavioral test. ( Chazot, PL; Ennaceur, A; Michalikova, S; van Rensburg, R, 2010) |
| "Pretreatment with lamotrigine significantly attenuated AMPH/CDP-induced effects, but also reduced motility when tested in the presence of CDP-alone." | 1.35 | Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania. ( Nielsen, AN; Redrobe, JP, 2009) |
| "Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups." | 1.35 | Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats. ( Choy, KH; van den Buuse, M, 2008) |
| "Aripiprazole is an atypical antipsychotic that acts as a partial agonist at the dopamine D(2) receptor." | 1.35 | Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. ( Guimarães, FS; Leite, JV; Moreira, FA, 2008) |
| " In addition the home cage behaviour of mice administered with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) using an acute dosing regimen was also investigated." | 1.33 | Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. ( Billinton, A; Brown, M; Chapman, H; Quinn, LP; Stean, TO; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2006) |
| "Pretreatment with riluzole 10 mg/kg, but not 3 mg/kg, had a moderately depressant effect both on spontaneous and amphetamine-induced locomotion." | 1.32 | Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. ( Dall'Igna, OP; Dietrich, MO; Hoffmann, A; Lara, DR; Lourenço Da Silva, A; Souza, DO, 2003) |
| " Thus, for example, NT69L after five daily injections at a fixed dosage was as effective at reversing cocaine-induced hyperactivity as after the first injection." | 1.32 | Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. ( Boules, M; Fauq, A; McCormick, D; McMahon, B; Richelson, E; Stewart, J; Wang, R; Warrington, L; Yerbury, S, 2003) |
| " They were challenged on the eighth day with one dosage and sacrificed 3 h later." | 1.32 | Activation of metabotropic glutamate receptor 5 is associated with effect of amphetamine on brain neurons. ( Li, LT; Lin, WW; Yin, HS; Yu, MF, 2003) |
| " At 7 weeks of age, dose-response curves were obtained with morphine (10, 31." | 1.30 | Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice. ( Luján Estrada, M; Medina Jiménez, M; Rodríguez, R, 1997) |
| "The mouse mutant coloboma (Cml+) exhibits profound spontaneous locomotor hyperactivity resulting from a deletion mutation." | 1.29 | Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. ( Collins, KA; Hess, EJ; Wilson, MC, 1996) |
| "When amphetamine therapy was combined systematically with conditioning experiments and psychosocial therapy, for long enough periods of time (many weeks), the beneficial effects of this drug persisted in the nodrug state, i." | 1.27 | Psychopharmacologic facilitation of psychosocial therapy of violence and hyperkinesis. ( Corson, EO; Corson, SA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 89 (42.58) | 18.7374 |
| 1990's | 11 (5.26) | 18.2507 |
| 2000's | 56 (26.79) | 29.6817 |
| 2010's | 49 (23.44) | 24.3611 |
| 2020's | 4 (1.91) | 2.80 |
| Authors | Studies |
|---|---|
| Szulczyk, D | 1 |
| Bielenica, A | 1 |
| Kędzierska, E | 1 |
| Leśniak, A | 1 |
| Pawłowska, A | 1 |
| Bujalska-Zadrożny, M | 1 |
| Saccone, I | 1 |
| Sparaco, R | 1 |
| Fiorino, F | 1 |
| Savchenko, O | 1 |
| Struga, M | 1 |
| Lobina, C | 1 |
| Maccioni, P | 1 |
| Lorrai, I | 1 |
| Zaru, A | 1 |
| Collu, M | 1 |
| Carai, MAM | 1 |
| Brizzi, A | 1 |
| Mugnaini, C | 1 |
| Gessa, GL | 1 |
| Corelli, F | 1 |
| Colombo, G | 1 |
| Sequeira-Cordero, A | 1 |
| Brenes, JC | 1 |
| Lange, HS | 1 |
| Vardigan, JD | 1 |
| Cannon, CE | 1 |
| Puri, V | 1 |
| Henze, DA | 1 |
| Uslaner, JM | 1 |
| Berezniuk, I | 1 |
| Rodriguiz, RM | 1 |
| Zee, ML | 1 |
| Marcus, DJ | 1 |
| Pintar, J | 1 |
| Morgan, DJ | 1 |
| Wetsel, WC | 1 |
| Fricker, LD | 1 |
| Mannangatti, P | 1 |
| Ramamoorthy, S | 1 |
| Jayanthi, LD | 1 |
| Albertini, G | 1 |
| Walrave, L | 1 |
| Demuyser, T | 1 |
| Massie, A | 1 |
| De Bundel, D | 1 |
| Smolders, I | 1 |
| Popkin, S | 1 |
| Nanchanatt, A | 1 |
| Mauterer, MI | 1 |
| Rhoads, DE | 1 |
| Han, L | 1 |
| Wang, L | 1 |
| Tang, S | 1 |
| Yuan, L | 1 |
| Wu, S | 1 |
| Du, X | 1 |
| Xiang, Y | 1 |
| Qu, X | 1 |
| Liu, H | 1 |
| Luo, H | 1 |
| Qin, X | 1 |
| Liu, C | 1 |
| Grimm, CM | 1 |
| Aksamaz, S | 1 |
| Schulz, S | 1 |
| Teutsch, J | 1 |
| Sicinski, P | 1 |
| Liss, B | 1 |
| Kätzel, D | 1 |
| Canseco-Alba, A | 1 |
| Schanz, N | 1 |
| Sanabria, B | 1 |
| Zhao, J | 1 |
| Lin, Z | 1 |
| Liu, QR | 1 |
| Onaivi, ES | 1 |
| Kara, NZ | 1 |
| Toker, L | 1 |
| Agam, G | 1 |
| Anderson, GW | 1 |
| Belmaker, RH | 2 |
| Einat, H | 2 |
| Sławińska, A | 1 |
| Wierońska, JM | 1 |
| Stachowicz, K | 2 |
| Marciniak, M | 1 |
| Lasoń-Tyburkiewicz, M | 1 |
| Gruca, P | 1 |
| Papp, M | 1 |
| Kusek, M | 1 |
| Tokarski, K | 2 |
| Doller, D | 1 |
| Pilc, A | 2 |
| Del'Guidice, T | 1 |
| Lemasson, M | 1 |
| Etiévant, A | 1 |
| Manta, S | 1 |
| Magno, LA | 1 |
| Escoffier, G | 1 |
| Roman, FS | 1 |
| Beaulieu, JM | 1 |
| Dolan, J | 1 |
| Mitchell, KJ | 1 |
| Byun, NE | 1 |
| Grannan, M | 1 |
| Bubser, M | 1 |
| Barry, RL | 1 |
| Thompson, A | 1 |
| Rosanelli, J | 1 |
| Gowrishankar, R | 1 |
| Kelm, ND | 1 |
| Damon, S | 1 |
| Bridges, TM | 1 |
| Melancon, BJ | 1 |
| Tarr, JC | 1 |
| Brogan, JT | 1 |
| Avison, MJ | 1 |
| Deutch, AY | 1 |
| Wess, J | 3 |
| Wood, MR | 1 |
| Lindsley, CW | 1 |
| Gore, JC | 1 |
| Conn, PJ | 1 |
| Jones, CK | 1 |
| Canal, CE | 1 |
| Morgan, D | 1 |
| Felsing, D | 1 |
| Kondabolu, K | 1 |
| Rowland, NE | 1 |
| Robertson, KL | 1 |
| Sakhuja, R | 1 |
| Booth, RG | 1 |
| Herrmann, AP | 1 |
| Benvenutti, R | 1 |
| Pilz, LK | 1 |
| Elisabetsky, E | 1 |
| Peng, XX | 1 |
| Lister, A | 1 |
| Rabinowitsch, A | 1 |
| Kolaric, R | 1 |
| Cabeza de Vaca, S | 1 |
| Ziff, EB | 1 |
| Carr, KD | 1 |
| Lin, SH | 1 |
| Chien, YC | 1 |
| Chiang, WW | 1 |
| Liu, YZ | 1 |
| Lien, CC | 1 |
| Chen, CC | 1 |
| Chou, S | 1 |
| Jones, S | 1 |
| Li, M | 2 |
| Timić Stamenić, T | 1 |
| Joksimović, S | 1 |
| Biawat, P | 1 |
| Stanković, T | 1 |
| Marković, B | 1 |
| Cook, JM | 2 |
| Savić, MM | 1 |
| Carli, M | 1 |
| Kostoula, C | 1 |
| Sacchetti, G | 1 |
| Mainolfi, P | 1 |
| Anastasia, A | 1 |
| Villani, C | 1 |
| Invernizzi, RW | 1 |
| Zimmerman, EC | 1 |
| Grace, AA | 3 |
| Engelhardt, KA | 1 |
| Fuchs, E | 1 |
| Schwarting, RKW | 1 |
| Wöhr, M | 1 |
| Pietropaolo, S | 1 |
| Feldon, J | 2 |
| Yee, BK | 1 |
| Vanover, KE | 1 |
| Veinbergs, I | 1 |
| Davis, RE | 1 |
| Pałucha-Poniewiera, A | 1 |
| Kłodzińska, A | 1 |
| Hess, G | 1 |
| Schann, S | 1 |
| Frauli, M | 1 |
| Neuville, P | 1 |
| Southam, E | 1 |
| Cilia, J | 1 |
| Gartlon, JE | 2 |
| Woolley, ML | 3 |
| Lacroix, LP | 1 |
| Jennings, CA | 1 |
| Cluderay, JE | 1 |
| Reavill, C | 2 |
| Rourke, C | 1 |
| Wilson, DM | 1 |
| Dawson, LA | 2 |
| Medhurst, AD | 1 |
| Jones, DN | 2 |
| Sabioni, P | 1 |
| Baretta, IP | 1 |
| Ninomiya, EM | 1 |
| Gustafson, L | 1 |
| Rodrigues, AL | 1 |
| Andreatini, R | 1 |
| Sun, T | 1 |
| Hu, G | 1 |
| Carter, HJ | 1 |
| Watson, JM | 1 |
| Tzavara, ET | 1 |
| Degroot, A | 1 |
| Wade, MR | 1 |
| Davis, RJ | 1 |
| Nomikos, GG | 1 |
| Redrobe, JP | 2 |
| Nielsen, AN | 1 |
| Galiñanes, GL | 1 |
| Taravini, IR | 1 |
| Murer, MG | 1 |
| Tsuchida, R | 1 |
| Kubo, M | 1 |
| Kuroda, M | 1 |
| Shibasaki, Y | 1 |
| Shintani, N | 2 |
| Abe, M | 1 |
| Köves, K | 1 |
| Hashimoto, H | 2 |
| Baba, A | 2 |
| Marchese, G | 1 |
| Casu, G | 1 |
| Casti, P | 1 |
| Spada, GP | 1 |
| Pani, L | 1 |
| Hall, DA | 1 |
| Powers, JP | 1 |
| Gulley, JM | 1 |
| Boulay, D | 1 |
| Bergis, O | 1 |
| Avenet, P | 1 |
| Griebel, G | 1 |
| Ennaceur, A | 1 |
| Michalikova, S | 1 |
| van Rensburg, R | 1 |
| Chazot, PL | 1 |
| Macedo, CE | 1 |
| Angst, MJ | 2 |
| Guiberteau, T | 1 |
| Brasse, D | 1 |
| O'Brien, TJ | 1 |
| Sandner, G | 2 |
| Valvassori, SS | 1 |
| Elias, G | 1 |
| de Souza, B | 1 |
| Petronilho, F | 1 |
| Dal-Pizzol, F | 1 |
| Kapczinski, F | 1 |
| Trzesniak, C | 1 |
| Tumas, V | 1 |
| Dursun, S | 1 |
| Chagas, MH | 1 |
| Hallak, JE | 1 |
| Zuardi, AW | 1 |
| Quevedo, J | 1 |
| Crippa, JA | 1 |
| Brotons, O | 1 |
| O'Daly, OG | 1 |
| Guindalini, C | 1 |
| Howard, M | 1 |
| Bubb, J | 1 |
| Barker, G | 1 |
| Dalton, J | 1 |
| Quinn, J | 1 |
| Murray, RM | 1 |
| Breen, G | 1 |
| Shergill, SS | 1 |
| Papaleo, F | 1 |
| Yang, F | 1 |
| Garcia, S | 1 |
| Chen, J | 1 |
| Lu, B | 1 |
| Crawley, JN | 1 |
| Weinberger, DR | 1 |
| Shi, X | 1 |
| McGinty, JF | 1 |
| Wesołowska, A | 1 |
| Partyka, A | 1 |
| Jastrzębska-Więsek, M | 1 |
| Kolarz, A | 2 |
| Mierzejewski, P | 1 |
| Bieńkowski, P | 1 |
| Kołaczkowski, M | 1 |
| Gravius, A | 1 |
| Laszy, J | 1 |
| Pietraszek, M | 1 |
| Sághy, K | 1 |
| Nagel, J | 1 |
| Chambon, C | 1 |
| Wegener, N | 1 |
| Valastro, B | 1 |
| Danysz, W | 1 |
| Gyertyán, I | 1 |
| Valenti, O | 1 |
| Lodge, DJ | 3 |
| Sagvolden, T | 1 |
| Dencker, D | 1 |
| Wörtwein, G | 1 |
| Weikop, P | 1 |
| Jeon, J | 1 |
| Thomsen, M | 1 |
| Sager, TN | 1 |
| Mørk, A | 1 |
| Woldbye, DP | 1 |
| Fink-Jensen, A | 1 |
| Naert, A | 1 |
| Callaerts-Vegh, Z | 1 |
| Moechars, D | 1 |
| Meert, T | 1 |
| D'Hooge, R | 1 |
| Rasmussen, B | 1 |
| Unterwald, EM | 2 |
| Rawls, SM | 1 |
| Gill, KM | 1 |
| Aras, S | 1 |
| Creson, TK | 1 |
| Austin, DR | 1 |
| Shaltiel, G | 1 |
| McCammon, J | 1 |
| Manji, HK | 1 |
| Chen, G | 1 |
| Douma, TN | 1 |
| Postma, Y | 1 |
| Olivier, B | 1 |
| Groenink, L | 1 |
| McFarland, K | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| Roux, S | 1 |
| Hay, AM | 1 |
| Porsolt, RD | 1 |
| Elster, L | 1 |
| Frederiksen, K | 1 |
| Bundgaard, C | 1 |
| de Jong, IE | 1 |
| Smith, GP | 1 |
| Bruun, AT | 1 |
| Larsen, PH | 1 |
| Didriksen, M | 1 |
| Gill, MJ | 2 |
| Arnold, JC | 1 |
| Cain, ME | 2 |
| van Gaalen, MM | 1 |
| Relo, AL | 1 |
| Mueller, BK | 1 |
| Gross, G | 1 |
| Mezler, M | 1 |
| Gupta, S | 1 |
| Khanna, VK | 1 |
| Maurya, A | 1 |
| Bawankule, DU | 1 |
| Shukla, RK | 1 |
| Pal, A | 1 |
| Srivastava, SK | 1 |
| Enman, NM | 1 |
| Benneyworth, MA | 1 |
| Coyle, JT | 2 |
| Cantrup, R | 1 |
| Sathanantham, K | 1 |
| Rushlow, WJ | 1 |
| Rajakumar, N | 1 |
| Mersmann, MG | 1 |
| Pittenger, ST | 1 |
| Perez, SM | 1 |
| Shah, A | 1 |
| Asher, A | 1 |
| Jean, A | 1 |
| Laurent, L | 1 |
| Bockaert, J | 1 |
| Charnay, Y | 1 |
| Dusticier, N | 1 |
| Nieoullon, A | 1 |
| Barrot, M | 1 |
| Neve, R | 1 |
| Compan, V | 1 |
| Coitinho, AS | 1 |
| Dietrich, MO | 2 |
| Hoffmann, A | 2 |
| Dall'Igna, OP | 3 |
| Souza, DO | 3 |
| Martins, VR | 1 |
| Brentani, RR | 1 |
| Izquierdo, I | 1 |
| Lara, DR | 3 |
| Balla, A | 1 |
| Sershen, H | 1 |
| Serra, M | 1 |
| Koneru, R | 1 |
| Javitt, DC | 1 |
| Avena, NM | 2 |
| Hoebel, BG | 2 |
| Lourenço Da Silva, A | 1 |
| Kusljic, S | 2 |
| Copolov, DL | 1 |
| van den Buuse, M | 4 |
| Muñoz, A | 1 |
| Lopez-Real, A | 1 |
| Labandeira-Garcia, JL | 1 |
| Guerra, MJ | 1 |
| Boules, M | 1 |
| McMahon, B | 1 |
| Wang, R | 1 |
| Warrington, L | 1 |
| Stewart, J | 1 |
| Yerbury, S | 1 |
| Fauq, A | 1 |
| McCormick, D | 1 |
| Richelson, E | 1 |
| Villégier, AS | 2 |
| Drouin, C | 2 |
| Bizot, JC | 1 |
| Marien, M | 1 |
| Glowinski, J | 2 |
| Colpaërt, F | 1 |
| Tassin, JP | 2 |
| Yu, MF | 1 |
| Lin, WW | 1 |
| Li, LT | 1 |
| Yin, HS | 2 |
| Lamango, NS | 1 |
| Ayuk-Takem, LT | 1 |
| Nesby, R | 1 |
| Zhao, WQ | 1 |
| Charlton, CG | 1 |
| Shin, DM | 1 |
| Korada, S | 1 |
| Raballo, R | 1 |
| Shashikant, CS | 1 |
| Simeone, A | 1 |
| Taylor, JR | 1 |
| Vaccarino, F | 1 |
| Dziedzicka-Wasylewska, M | 1 |
| Faron-Górecka, A | 1 |
| Rogóz, Z | 1 |
| Solich, J | 1 |
| Silva, RC | 1 |
| Knobloch, J | 1 |
| Danion, JM | 1 |
| Jeltsch, H | 1 |
| Lazarus, C | 1 |
| Cosquer, B | 1 |
| Galani, R | 1 |
| Cassel, JC | 1 |
| Lautar, SL | 1 |
| Rojas, C | 1 |
| Slusher, BS | 1 |
| Wozniak, KM | 1 |
| Wu, Y | 1 |
| Thomas, AG | 1 |
| Waldon, D | 1 |
| Li, W | 1 |
| Ferraris, D | 1 |
| Belyakov, S | 1 |
| Tort, AB | 1 |
| Quinn, LP | 1 |
| Stean, TO | 1 |
| Chapman, H | 1 |
| Brown, M | 1 |
| Vidgeon-Hart, M | 1 |
| Upton, N | 1 |
| Billinton, A | 1 |
| Virley, DJ | 1 |
| Tanaka, K | 1 |
| Kawagishi, N | 1 |
| Ago, Y | 1 |
| Matsuda, T | 1 |
| Hashimoto, R | 1 |
| Kunugi, H | 1 |
| Yamamoto, A | 1 |
| Kawaguchi, C | 1 |
| Shimada, T | 1 |
| Chi, H | 1 |
| Jang, JK | 1 |
| Kim, JH | 3 |
| Vezina, P | 2 |
| Chen, K | 1 |
| Kalpana, S | 1 |
| Shih, JC | 1 |
| Sevak, RJ | 1 |
| Owens, WA | 1 |
| Koek, W | 1 |
| Galli, A | 1 |
| Daws, LC | 1 |
| France, CP | 1 |
| Choy, KH | 1 |
| Yates, JW | 1 |
| Meij, JT | 1 |
| Sullivan, JR | 1 |
| Richtand, NM | 1 |
| Yu, L | 1 |
| Stasi, MA | 1 |
| Di Serio, S | 1 |
| Vertechy, M | 1 |
| Schiavone, A | 1 |
| Ghirardi, O | 1 |
| Minetti, P | 1 |
| Campiani, G | 1 |
| Borsini, F | 1 |
| Carminati, P | 1 |
| Müller Smith, K | 1 |
| Fagel, DM | 1 |
| Stevens, HE | 1 |
| Rabenstein, RL | 1 |
| Maragnoli, ME | 1 |
| Ohkubo, Y | 1 |
| Picciotto, MR | 1 |
| Schwartz, ML | 1 |
| Vaccarino, FM | 1 |
| Leite, JV | 1 |
| Guimarães, FS | 1 |
| Moreira, FA | 1 |
| Pemberton, DJ | 1 |
| Bate, S | 1 |
| Corti, C | 1 |
| Kim, WY | 2 |
| Kim, S | 1 |
| Egerton, A | 1 |
| Reid, L | 1 |
| McGregor, S | 1 |
| Cochran, SM | 1 |
| Morris, BJ | 1 |
| Pratt, JA | 1 |
| Martin, S | 1 |
| Rouillon, C | 1 |
| Abraini, JH | 1 |
| David, HN | 1 |
| Speciale, SG | 1 |
| Karoum, F | 1 |
| Wyatt, RJ | 1 |
| Wray, SR | 2 |
| Melville, GN | 1 |
| Grell, GA | 1 |
| Edge, PC | 1 |
| Hrishi Keshavan, HJ | 1 |
| Gurbani, NK | 1 |
| Dandiya, PC | 1 |
| Lin, MT | 1 |
| Chan, HK | 1 |
| Chen, CF | 1 |
| Teh, GW | 1 |
| Jolicoeur, FB | 1 |
| De Michele, G | 1 |
| Barbeau, A | 1 |
| St-Pierre, S | 1 |
| Helmeste, DM | 1 |
| Seeman, P | 1 |
| Ridley, RM | 1 |
| Baker, HF | 1 |
| Smith, DF | 1 |
| Sostek, AJ | 1 |
| Buchsbaum, MS | 1 |
| Rapoport, JL | 2 |
| Iakimovskiĭ, AF | 1 |
| Hess, EJ | 1 |
| Collins, KA | 1 |
| Wilson, MC | 2 |
| Medina Jiménez, M | 1 |
| Luján Estrada, M | 1 |
| Rodríguez, R | 1 |
| Bailey, CP | 1 |
| Manley, SJ | 1 |
| Watson, WP | 1 |
| Wonnacott, S | 1 |
| Molleman, A | 1 |
| Little, HJ | 1 |
| Hatcher, JP | 1 |
| Lewis, VA | 1 |
| Sanger, GJ | 1 |
| Hagan, J | 1 |
| Ahmed, SH | 1 |
| Stinus, L | 1 |
| Cador, M | 1 |
| Mamczarz, J | 1 |
| Budziszewska, B | 1 |
| Antkiewicz-Michaluk, L | 2 |
| Vetulani, J | 2 |
| Carlsson, ML | 1 |
| Martin, P | 1 |
| Nilsson, M | 1 |
| Sorensen, SM | 1 |
| Carlsson, A | 1 |
| Waters, S | 1 |
| Waters, N | 1 |
| Steffensen, SC | 1 |
| Henriksen, SJ | 1 |
| Khisti, RT | 1 |
| Chopde, CT | 1 |
| Abraham, E | 1 |
| Lacroix, L | 1 |
| Spinelli, S | 1 |
| White, W | 1 |
| Shaldivin, A | 1 |
| Kaptsan, A | 1 |
| Grisaru, N | 1 |
| Swerdlow, NR | 2 |
| Halim, N | 1 |
| Hanlon, FM | 1 |
| Platten, A | 1 |
| Auerbach, PP | 1 |
| Nalepa, I | 1 |
| Sansone, M | 1 |
| Mao, L | 1 |
| Conquet, F | 1 |
| Wang, JQ | 1 |
| Stanhope, KJ | 1 |
| Mirza, NR | 1 |
| Bickerdike, MJ | 1 |
| Bright, JL | 1 |
| Harrington, NR | 1 |
| Hesselink, MB | 1 |
| Kennett, GA | 1 |
| Lightowler, S | 1 |
| Sheardown, MJ | 1 |
| Syed, R | 1 |
| Upton, RL | 1 |
| Wadsworth, G | 1 |
| Weiss, SM | 1 |
| Wyatt, A | 1 |
| Blanc, G | 1 |
| Silbergeld, EK | 3 |
| Bareggi, SR | 2 |
| Becker, RE | 2 |
| Ginsburg, BE | 1 |
| Genovese, E | 2 |
| Leonard, BE | 1 |
| Ginsburg, B | 1 |
| Poitou, P | 1 |
| Boulu, R | 1 |
| Bohuon, C | 1 |
| Brase, DA | 1 |
| Loh, HH | 1 |
| Feinberg, M | 1 |
| Carroll, BJ | 1 |
| Kuczenski, R | 1 |
| Schmidt, D | 1 |
| Leith, N | 1 |
| Alpern, HP | 1 |
| Greer, CA | 1 |
| Mikkelsen, EJ | 1 |
| Ebert, MH | 1 |
| Brown, GL | 1 |
| Weise, VK | 1 |
| Kopin, IJ | 1 |
| Barkley, RA | 1 |
| Schlemmer, RF | 1 |
| Casper, RC | 1 |
| Siemsen, FK | 1 |
| Garver, DL | 1 |
| Davis, JM | 1 |
| Saletu, B | 2 |
| Bower, KB | 1 |
| Mercer, CD | 1 |
| Allen, RP | 1 |
| Safer, D | 1 |
| Covi, L | 1 |
| Oettinger, L | 3 |
| Saletu, M | 1 |
| Simeon, J | 1 |
| Viamontes, G | 1 |
| Itil, TM | 1 |
| Gross, MD | 1 |
| Krylov, SS | 1 |
| Petrov, AN | 1 |
| Pososinovikova, MP | 1 |
| Flemenbaum, A | 1 |
| Cerný, L | 1 |
| Kucerová, Z | 1 |
| Sturma, J | 1 |
| Roberts, DC | 1 |
| Zis, AP | 1 |
| Fibiger, HC | 1 |
| Egbe, P | 1 |
| Stableford, W | 1 |
| Butz, R | 1 |
| Leitenberg, H | 1 |
| Peyser, J | 1 |
| Soong, WJ | 1 |
| Hwang, BT | 1 |
| Tsai, WJ | 1 |
| Deng, JF | 1 |
| Bristow, LJ | 1 |
| Baucutt, L | 1 |
| Thorn, L | 1 |
| Hutson, PH | 1 |
| Noble, A | 1 |
| Beer, M | 1 |
| Middlemiss, DN | 1 |
| Tricklebank, MD | 1 |
| Pulvirenti, L | 1 |
| Koob, GF | 1 |
| Corson, SA | 2 |
| Corson, EO | 2 |
| Matsubara, K | 1 |
| Denhoff, E | 1 |
| Kinsbourne, M | 1 |
| Huestis, RD | 1 |
| Arnold, LE | 5 |
| Sroufe, LA | 1 |
| Stewart, MA | 1 |
| Snyder, SH | 2 |
| Taylor, KM | 1 |
| Meyerhoff, JL | 1 |
| Baldessarini, RJ | 1 |
| Newell, GR | 1 |
| Henderson, BE | 1 |
| Wender, PH | 3 |
| Schlechter, JM | 1 |
| Butcher, LL | 1 |
| Grahame-Smith, DG | 1 |
| DeLong, AR | 1 |
| McCloskey, K | 1 |
| Kirilcuk, V | 1 |
| Strobl, D | 1 |
| Weisenberg, A | 1 |
| Steinfels, P | 1 |
| Lightfoot, OB | 1 |
| Reece, RM | 1 |
| Chapel, JL | 1 |
| Verret, S | 1 |
| Glós, J | 1 |
| Ramer, CM | 1 |
| Peters, JE | 1 |
| Campbell, WE | 1 |
| Goldberg, AM | 2 |
| Randrup, A | 1 |
| Munkvad, I | 1 |
| Kornetsky, C | 1 |
| Claghorn, J | 1 |
| Neblett, C | 1 |
| Sutter, E | 1 |
| Farrell, G | 1 |
| Kraft, I | 1 |
| Barkai, A | 1 |
| Pond, DA | 1 |
| Lingjaerde, O | 1 |
| McCabe, ER | 1 |
| McCabe, L | 1 |
| Howell, MC | 1 |
| Rever, GW | 1 |
| Scholl, ML | 1 |
| Trowbridge, F | 1 |
| Rutledge, A | 1 |
| Akins, K | 1 |
| Turner, EJ | 1 |
| Duvernoy, WF | 1 |
| Tec, L | 1 |
| Levy, HB | 1 |
| Tinklenberg, JR | 1 |
| Conners, CK | 1 |
| Mac Keith, RC | 1 |
| Fog, R | 1 |
| Pakkenberg, H | 1 |
| Ladisich, W | 2 |
| Volbehr, H | 2 |
| Matussek, N | 2 |
| Ganguly, DK | 1 |
| Malhtora, CL | 1 |
| Pelczarska, A | 1 |
| Novick, I | 1 |
| Pihl, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders[NCT06167577] | 150 participants (Actual) | Observational | 2018-11-08 | Completed | |||
| Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials[NCT02695355] | Phase 2 | 87 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
15 reviews available for amphetamine and Hyperactivity, Motor
| Article | Year |
|---|---|
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance | 1981 |
Stereotypy in monkeys and humans.
Topics: Amphetamine; Animals; Callithrix; Child; Chlorocebus aethiops; Cognition; Dopamine; Haplorhini; Huma | 1982 |
Lithium and motor activity of animals: effects and possible mechanism of action.
Topics: Amphetamine; Animals; Circadian Rhythm; Dopamine; Exploratory Behavior; Humans; Hyperkinesis; Lithiu | 1980 |
Neuropharmacology of hyperkinesis.
Topics: Amphetamine; Animals; Barbiturates; Behavior; Brain Chemistry; Central Nervous System; Child; Humans | 1977 |
Pharmacological and biochemical aspects of hyperkinetic disorders.
Topics: Amphetamine; Animals; Behavior; Central Nervous System Stimulants; Humans; Hyperkinesis | 1979 |
Predicting the response of hyperkinetic children to stimulant drugs: a review.
Topics: Amphetamine; Amphetamines; Child; Clinical Trials as Topic; Dextroamphetamine; Electroencephalograph | 1976 |
Effects of psychostimulants on aggression.
Topics: Adolescent; Aggression; Amphetamine; Animals; Child; Dextroamphetamine; Dogs; Dose-Response Relation | 1975 |
Treating problem children with stimulant drugs.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 1973 |
Symposium: behavior modification by drugs. I. Pharmacology of the amphetamines.
Topics: Amphetamine; Animals; Arousal; Catecholamines; Central Nervous System; Child; Child, Preschool; Cons | 1972 |
What have we learned from psychoactive drug research on hyperactives?
Topics: Amphetamine; Antidepressive Agents; Child; Clinical Trials as Topic; Evaluation Studies as Topic; Hu | 1972 |
Minimal brain dysfunction in children. Diagnosis and management.
Topics: Abnormalities, Multiple; Affective Symptoms; Age Factors; Amphetamine; Attention; Attention Deficit | 1973 |
Pharmacological studies on the brain mechanisms underlying two forms of behavioral excitation: stereotyped hyperactivity and "rage".
Topics: Aggression; Amphetamine; Anger; Animals; Basal Ganglia; Behavior, Animal; Brain; Brain Chemistry; Di | 1969 |
Psychoactive drugs in the immature organism.
Topics: Amphetamine; Animals; Autistic Disorder; Behavior, Animal; Catecholamines; Child; Child Behavior; Ch | 1970 |
[Stimulants in the treatment of hyperkinetic behavior disorders].
Topics: Amphetamine; Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Humans; Hyperkine | 1971 |
Behaviour disorders in brain-damaged children.
Topics: Adolescent; Age Factors; Amphetamine; Anticonvulsants; Brain Damage, Chronic; Brain Injuries; Child; | 1967 |
15 trials available for amphetamine and Hyperactivity, Motor
| Article | Year |
|---|---|
Modulation of orbitofrontal response to amphetamine by a functional variant of DAT1 and in vitro confirmation.
Topics: Amphetamine; Decision Making; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitor | 2011 |
Effects of amphetamine on vigilance performance in normal and hyperactive children.
Topics: Age Factors; Amphetamine; Attention; Child; Double-Blind Method; Humans; Hyperkinesis; Male | 1980 |
Effects of dopamine agonists and antagonists in Tourette's disease.
Topics: Adolescent; Adult; Amphetamine; Apomorphine; Child; Clinical Trials as Topic; Dextroamphetamine; Dop | 1979 |
Urinary catecholamines and amphetamine excretion in hyperactive and normal boys.
Topics: Amphetamine; Child; Dextroamphetamine; Dopamine; Epinephrine; Homovanillic Acid; Humans; Hyperkinesi | 1978 |
Predicting the response of hyperkinetic children to stimulant drugs: a review.
Topics: Amphetamine; Amphetamines; Child; Clinical Trials as Topic; Dextroamphetamine; Electroencephalograph | 1976 |
The use of amphetamines in hyperactivity.
Topics: Amphetamine; Child; Clinical Trials as Topic; Humans; Hyperkinesis | 1975 |
Comparative symptomatological and evoked potential studies with d-amphetamine, thioridazine, and placebo in hyperkinetic children.
Topics: Administration, Oral; Adolescent; Amphetamine; Anxiety; Child; Child Behavior; Clinical Trials as To | 1975 |
A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
Topics: Adolescent; Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, P | 1976 |
What have we learned from psychoactive drug research on hyperactives?
Topics: Amphetamine; Antidepressive Agents; Child; Clinical Trials as Topic; Evaluation Studies as Topic; Hu | 1972 |
Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms.
Topics: Aggression; Amphetamine; Attention; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; | 1972 |
Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs.
Topics: Aggression; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; C | 1973 |
Hyperkinetic adult. Study of the "paradoxical" amphetamine response.
Topics: Adult; Age Factors; Amphetamine; Anxiety; Depression; Dextroamphetamine; Humans; Hyperkinesis; Male; | 1972 |
Psychoactive drugs in the immature organism.
Topics: Amphetamine; Animals; Autistic Disorder; Behavior, Animal; Catecholamines; Child; Child Behavior; Ch | 1970 |
The effect of drugs on hyperactivity in children with some observations of changes in mineral metabolism.
Topics: Acetazolamide; Adolescent; Amphetamine; Analysis of Variance; Child; Child, Preschool; Chlorides; Cl | 1971 |
Effect of amphetamine on the septal syndrome in rats.
Topics: Amphetamine; Animals; Avoidance Learning; Behavior, Animal; Cerebral Ventricles; Fear; Humans; Hyper | 1969 |
182 other studies available for amphetamine and Hyperactivity, Motor
| Article | Year |
|---|---|
G protein-coupled receptor binding and pharmacological evaluation of indole-derived thiourea compounds.
Topics: Amphetamine; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Crystallog | 2020 |
Suppressing effect of the novel positive allosteric modulator of the GABA
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Cocaine; Dopamine Uptake | 2021 |
Time-dependent changes in striatal monoamine levels and gene expression following single and repeated amphetamine administration in rats.
Topics: Amphetamine; Animals; Anticipation, Psychological; Behavior, Animal; Biogenic Monoamines; Central Ne | 2021 |
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.
Topics: Alzheimer Disease; Amphetamine; Animals; Association Learning; Behavior, Animal; Central Nervous Sys | 2021 |
ProSAAS-derived peptides are regulated by cocaine and are required for sensitization to the locomotor effects of cocaine.
Topics: Amphetamine; Animals; Cocaine; Conditioning, Operant; Dopamine Uptake Inhibitors; Dose-Response Rela | 2017 |
Interference of norepinephrine transporter trafficking motif attenuates amphetamine-induced locomotor hyperactivity and conditioned place preference.
Topics: Amino Acid Motifs; Amphetamine; Animals; Central Nervous System Stimulants; Conditioning, Operant; E | 2018 |
6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain.
Topics: Amphetamine; Animals; Body Weight; Brain; Central Nervous System Stimulants; Cornea; Disease Models, | 2018 |
Co-administration of amphetamine with alcohol results in decreased alcohol withdrawal severity in adolescent rats.
Topics: Alcohol Drinking; Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; D | 2018 |
ITGB4 deficiency in bronchial epithelial cells directs airway inflammation and bipolar disorder-related behavior.
Topics: Amphetamine; Animals; Anti-Bacterial Agents; Bipolar Disorder; Bronchitis; Disease Models, Animal; D | 2018 |
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.
Topics: Amino Acids; Amphetamine; Animals; Attention; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyc | 2018 |
Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.
Topics: Amphetamine; Animals; Cannabinoids; Central Nervous System Stimulants; Cocaine; Conditioning, Operan | 2019 |
Trehalose induced antidepressant-like effects and autophagy enhancement in mice.
Topics: Amphetamine; Analysis of Variance; Animals; Antidepressive Agents; Autophagy; Brain; Central Nervous | 2013 |
The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.
Topics: Allosteric Regulation; Amphetamine; Anilides; Animals; Antipsychotic Agents; Cyclohexanecarboxylic A | 2013 |
Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice.
Topics: Amphetamine; Analysis of Variance; Animals; Atomoxetine Hydrochloride; Central Nervous System Stimul | 2014 |
Mutation of Elfn1 in mice causes seizures and hyperactivity.
Topics: Amphetamine; Animals; Axons; Brain; Cerebral Cortex; Gene Expression; Gene Order; Gene Targeting; Ge | 2013 |
Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
Topics: Amphetamine; Animals; Antipsychotic Agents; Blood Pressure; Brain; Cell Line, Transformed; Central N | 2014 |
A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
Topics: 2-Naphthylamine; Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Feed | 2014 |
N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice.
Topics: Acetylcysteine; Amphetamine; Analysis of Variance; Animals; Central Nervous System; Central Nervous | 2014 |
Episodic sucrose intake during food restriction increases synaptic abundance of AMPA receptors in nucleus accumbens and augments intake of sucrose following restoration of ad libitum feeding.
Topics: Amphetamine; Analysis of Variance; Animals; Body Weight; Central Nervous System Stimulants; Eating; | 2015 |
Genetic mapping of ASIC4 and contrasting phenotype to ASIC1a in modulating innate fear and anxiety.
Topics: Acid Sensing Ion Channels; Amphetamine; Animals; Anxiety; Body Composition; Eating; Estrogen Antagon | 2015 |
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; C | 2015 |
Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion.
Topics: Amphetamine; Animals; Behavior, Animal; Benzodiazepines; Cognition Disorders; Dizocilpine Maleate; H | 2015 |
Tph2 gene deletion enhances amphetamine-induced hypermotility: effect of 5-HT restoration and role of striatal noradrenaline release.
Topics: 5-Hydroxytryptophan; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Carbidopa; Corpus Striatum; | 2015 |
The Nucleus Reuniens of the Midline Thalamus Gates Prefrontal-Hippocampal Modulation of Ventral Tegmental Area Dopamine Neuron Activity.
Topics: Action Potentials; Amphetamine; Anesthetics, Inhalation; Anesthetics, Local; Animals; Central Nervou | 2016 |
Effects of amphetamine on pro-social ultrasonic communication in juvenile rats: Implications for mania models.
Topics: Amphetamine; Analysis of Variance; Animals; Avoidance Learning; Central Nervous System Stimulants; D | 2017 |
Nonphysical contact between cagemates alleviates the social isolation syndrome in C57BL/6 male mice.
Topics: Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Central Nervous | 2008 |
Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzoxazines; Co | 2008 |
Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Cyclopentanes; Disease M | 2008 |
Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.
Topics: Administration, Oral; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Do | 2009 |
The antimanic-like effect of tamoxifen: Behavioural comparison with other PKC-inhibiting and antiestrogenic drugs.
Topics: Amphetamine; Analysis of Variance; Animals; Antimanic Agents; Behavior, Animal; Benzophenanthridines | 2008 |
Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; | 2009 |
Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
Topics: Amphetamine; Animals; Hyperkinesis; Mice; Mice, Knockout; Muscarinic Agonists; Pyridines; Receptor, | 2009 |
CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Dizocilpine Maleate; Dopamine; Dopamin | 2009 |
Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
Topics: Amphetamine; Animals; Anticonvulsants; Antimanic Agents; Benzamides; Bipolar Disorder; Carbamates; C | 2009 |
Dopamine-dependent periadolescent maturation of corticostriatal functional connectivity in mouse.
Topics: Action Potentials; Age Factors; Amphetamine; Animals; Animals, Newborn; Cerebral Cortex; Corpus Stri | 2009 |
An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Atomoxetine Hydrochloride; Central Nervous Syste | 2009 |
Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Chemistry, Pharmaceutical; | 2009 |
Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat.
Topics: Amphetamine; Analysis of Variance; Animals; Benzazepines; Catheters, Indwelling; Dopamine; Dopamine | 2009 |
The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Clozapine | 2010 |
Distinguishing anxiolysis and hyperactivity in an open space behavioral test.
Topics: Amphetamine; Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Central | 2010 |
Acoustic hypersensitivity in adult rats after neonatal ventral hippocampus lesions.
Topics: Acoustic Stimulation; Age Factors; Amphetamine; Analysis of Variance; Animals; Auditory Pathways; Co | 2010 |
Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.
Topics: Amphetamine; Animals; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cannabi | 2011 |
Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways.
Topics: Action Potentials; Amphetamine; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Carrier | 2012 |
D1 and D2 dopamine receptors differentially mediate the activation of phosphoproteins in the striatum of amphetamine-sensitized rats.
Topics: Amphetamine; Animals; Area Under Curve; Behavior, Animal; Benzazepines; Central Nervous System Stimu | 2011 |
Tail suspension test does not detect antidepressant-like properties of atypical antipsychotics.
Topics: Amphetamine; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Central Nervous | 2011 |
Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
Topics: Alzheimer Disease; Amphetamine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; F | 2011 |
Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus.
Topics: Action Potentials; Amphetamine; Analysis of Variance; Animals; Dopamine; Dopamine Uptake Inhibitors; | 2011 |
Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD).
Topics: Amphetamine; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Disease Models, Anim | 2011 |
Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Central Nervous System Stimulants; Hyp | 2011 |
Vglut2 haploinsufficiency enhances behavioral sensitivity to MK-801 and amphetamine in mice.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Dizocilpine Maleate; Fema | 2011 |
Glutamate transporter subtype 1 (GLT-1) activator ceftriaxone attenuates amphetamine-induced hyperactivity and behavioral sensitization in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Ceftriaxone; Central Nervous System Sensitization; Central N | 2011 |
A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Benzodiazepines; Diazepam; Disease Models, Animal; Dopa | 2011 |
Lithium treatment attenuates muscarinic M(1) receptor dysfunction.
Topics: Amphetamine; Analysis of Variance; Animals; Antimanic Agents; Cells, Cultured; Cerebral Cortex; Drug | 2011 |
The amphetamine-chlordiazepoxide mixture, a pharmacological screen for mood stabilizers, does not enhance amphetamine-induced disruption of prepulse inhibition.
Topics: Acoustic Stimulation; Affect; Amphetamine; Analysis of Variance; Animals; Anticonvulsants; Antimanic | 2011 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Models for assessing antipsychotics: antagonism of amphetamine-induced hyperactivity and stereotypies in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Disease Models, Animal; Hyperkinesis; Male; Mice; Stereo | 2001 |
Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.
Topics: Amphetamine; Animals; Benzodiazepines; Central Nervous System Stimulants; CHO Cells; Cognition Disor | 2012 |
Impact of mGluR5 during amphetamine-induced hyperactivity and conditioned hyperactivity in differentially reared rats.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Dose-Response Relationshi | 2012 |
NOGO-66 receptor deficient mice show slow acquisition of spatial memory task performance.
Topics: Alzheimer Disease; Amphetamine; Animals; Eating; Female; Fever; Hyperkinesis; Male; Maze Learning; M | 2012 |
Bioactivity guided isolation of antipsychotic constituents from the leaves of Rauwolfia tetraphylla L.
Topics: Amphetamine; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Hydrogen-Ion C | 2012 |
Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse.
Topics: Amphetamine; Animals; Brain; Central Nervous System Stimulants; Glycogen Synthase Kinase 3; Hyperkin | 2012 |
Altered acquisition and extinction of amphetamine-paired context conditioning in genetic mouse models of altered NMDA receptor function.
Topics: Amphetamine; Analysis of Variance; Animals; Behavioral Symptoms; Central Nervous System Stimulants; | 2012 |
Chronic hyperdopaminergic activity of schizophrenia is associated with increased ΔFosB levels and cdk-5 signaling in the nucleus accumbens.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Apomorphine; Blotting, Western; Chroni | 2012 |
Dose-dependent effects of differential rearing on amphetamine-induced hyperactivity.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Dose-Response Relationshi | 2012 |
Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Animals, Newborn; Attention Deficit Disorder with Hyperacti | 2013 |
The nucleus accumbens 5-HTR₄-CART pathway ties anorexia to hyperactivity.
Topics: Amphetamine; Animals; Anorexia; Cocaine; Hyperkinesis; Male; Mice; Mice, Knockout; N-Methyl-3,4-meth | 2012 |
Decreased hyperlocomotion induced by MK-801, but not amphetamine and caffeine in mice lacking cellular prion protein (PrP(C)).
Topics: Amphetamine; Animals; Caffeine; Dizocilpine Maleate; Dopamine Agonists; Down-Regulation; Excitatory | 2002 |
Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Dopamine; Drug Synergism; | 2003 |
Amphetamine-sensitized rats show sugar-induced hyperactivity (cross-sensitization) and sugar hyperphagia.
Topics: Amphetamine; Animals; Hyperkinesis; Hyperphagia; Male; Rats; Rats, Sprague-Dawley; Sucrose | 2003 |
Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Dizocilpine Maleate | 2003 |
Differential role of serotonergic projections arising from the dorsal and median raphe nuclei in locomotor hyperactivity and prepulse inhibition.
Topics: 5,7-Dihydroxytryptamine; Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Behavior, | 2003 |
Interaction between the noradrenergic and serotonergic systems in locomotor hyperactivity and striatal expression of Fos induced by amphetamine in rats.
Topics: Adrenergic alpha-Antagonists; Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimula | 2003 |
Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier.
Topics: Amphetamine; Animals; Behavior, Animal; Blood Glucose; Blood-Brain Barrier; Body Temperature; Brain; | 2003 |
Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Benzopyrans; Cerebellum; Dopamine; Dopami | 2003 |
Activation of metabotropic glutamate receptor 5 is associated with effect of amphetamine on brain neurons.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Behavior, Animal; Brain; Cells, Cultured; Centr | 2003 |
A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Behavior, Animal; Central Nervous System Stimul | 2003 |
Inhibition mechanism of S-adenosylmethionine-induced movement deficits by prenylcysteine analogs.
Topics: Amphetamine; Animals; Body Temperature; Central Nervous System Stimulants; Cystine; Drug Synergism; | 2003 |
Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice.
Topics: Adrenergic alpha-Agonists; Amphetamine; Animals; Cell Differentiation; Cell Division; Frontal Lobe; | 2004 |
The effect of combined treatment with imipramine and amantadine on the behavioral reactivity of central alpha1-adrenergic system in rats.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Aggression; Amantadine; Amphetamine; Ani | 2004 |
Prenatal exposure of Long-Evans rats to 17alpha-ethinylestradiol modifies neither latent inhibition nor prepulse inhibition of the startle reflex but elicits minor deficits in exploratory behavior.
Topics: Amphetamine; Animals; Animals, Newborn; Avoidance Learning; Behavior, Animal; Brain; Conditioning, P | 2004 |
No facilitation of amphetamine- or cocaine-induced hyperactivity in adult rats after various 192 IgG-saporin lesions in the basal forebrain.
Topics: Acetylcholinesterase; Amphetamine; Animals; Antibodies, Monoclonal; Basal Nucleus of Meynert; Centra | 2004 |
Functional dissociation between serotonergic pathways in dorsal and ventral hippocampus in psychotomimetic drug-induced locomotor hyperactivity and prepulse inhibition in rats.
Topics: Amphetamine; Animals; Hallucinogens; Hippocampus; Hyperkinesis; Male; Neural Inhibition; Neural Path | 2004 |
DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice.
Topics: Amphetamine; Animals; Aza Compounds; Azetidines; Behavior, Animal; Diabetes Mellitus; Dipeptidyl-Pep | 2005 |
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Central Nervous Sys | 2005 |
Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Automation; Behavio | 2006 |
Psychostimulant-induced attenuation of hyperactivity and prepulse inhibition deficits in Adcyap1-deficient mice.
Topics: Acoustic Stimulation; Amphetamine; Animals; Central Nervous System Stimulants; Hyperkinesis; Mice; P | 2006 |
Blockade of group II metabotropic glutamate receptors in the nucleus accumbens produces hyperlocomotion in rats previously exposed to amphetamine.
Topics: Amino Acids; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Bridged Bicyclo Compounds | 2006 |
Differential effects of chronic amphetamine and baclofen administration on cAMP levels and phosphorylation of CREB in distinct brain regions of wild type and monoamine oxidase B-deficient mice.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Baclofen; Biogenic Monoamines; Brain; Central N | 2006 |
Evidence for D2 receptor mediation of amphetamine-induced normalization of locomotion and dopamine transporter function in hypoinsulinemic rats.
Topics: Amphetamine; Animals; Blood Glucose; Brain; Brain Chemistry; Diabetes Mellitus, Experimental; Dopami | 2007 |
Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamine; Animals; Animals, Newborn; Apomorphine; Autorad | 2008 |
Bimodal effect of amphetamine on motor behaviors in C57BL/6 mice.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Behavior, Animal; Brain; Central Nervous System | 2007 |
ST2472: a new potential antipsychotic with very low liability to induce side-effects.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Anim | 2008 |
Deficiency in inhibitory cortical interneurons associates with hyperactivity in fibroblast growth factor receptor 1 mutant mice.
Topics: Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Cell Count; Central Nervous System Stim | 2008 |
Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Central Nervous System Stimulan | 2008 |
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.
Topics: Amino Acids; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Bridged Bicyclo Compounds | 2008 |
Chronic microinjection of valproic acid into the nucleus accumbens attenuates amphetamine-induced locomotor activity.
Topics: Amphetamine; Animals; Anticonvulsants; Central Nervous System Stimulants; Disease Models, Animal; Dr | 2008 |
Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.
Topics: Amphetamine; Animals; Attention; Behavior, Animal; Central Nervous System Stimulants; Cognition Diso | 2008 |
Blockade of group II, but not group I, mGluRs in the rat nucleus accumbens inhibits the expression of conditioned hyperactivity in an amphetamine-associated environment.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Psychologic | 2008 |
Phencyclidine-induced locomotor hyperactivity is enhanced in mice after stereotaxic brain serotonin depletion.
Topics: 5,7-Dihydroxytryptamine; Acoustic Stimulation; Adrenergic Uptake Inhibitors; Amphetamine; Animals; B | 2008 |
Prefrontal cortex and basolateral amygdala modulation of dopamine-mediated locomotion in the nucleus accumbens core.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Amygdala; Anesthetics, Local; Animals; Dopamine; Dopamine | 2008 |
Different effects of amphetamine and amfonelic acid on peripheral and central catecholamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Butyrolactone; Amphetamine; Animals; Brain; Catecholamines; Caudat | 1980 |
Neurochemical effects of danitracen (WA-355): mechanism of action.
Topics: Amphetamine; Animals; Apomorphine; Brain Chemistry; Humans; Hydroxyindoleacetic Acid; Hyperkinesis; | 1982 |
Involvement of both opiate and catecholaminergic receptors in the behavioural excitation provoked by thyrotropin-releasing hormone: comparisons with amphetamine.
Topics: Amphetamine; Animals; Behavior, Animal; Haloperidol; Humans; Hyperkinesis; Male; Naloxone; Propranol | 1983 |
Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation.
Topics: Amphetamine; Animals; Apomorphine; Dopamine; Humans; Hyperkinesis; Male; Neurotensin; Nomifensine; R | 1983 |
Genetic differences in brain dopamine receptors and amphetamine response: possible model for hyperkinetic children.
Topics: Amphetamine; Animals; Child; Disease Models, Animal; Humans; Hyperkinesis; Male; Mice; Mice, Inbred | 1983 |
[The effect of the activation and blockade of the neostriatal dopaminergic system on the hyperkinesis evoked in rats by the intrastriatal administration of picrotoxin].
Topics: Amphetamine; Animals; Chorea; Haloperidol; Hyperkinesis; Male; Metoclopramide; Microinjections; Myoc | 1993 |
Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation.
Topics: Amphetamine; Animals; Behavior, Animal; Coloboma; Disease Models, Animal; Dopamine Agonists; Gene Ex | 1996 |
Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice.
Topics: Amphetamine; Animals; Animals, Newborn; Animals, Suckling; Dose-Response Relationship, Drug; Drug Re | 1997 |
Chronic ethanol administration alters activity in ventral tegmental area neurons after cessation of withdrawal hyperexcitability.
Topics: Action Potentials; Amphetamine; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Ethanol; Hyperk | 1998 |
5-HT4 receptor antagonism does not affect motor and reward mechanisms in the rat.
Topics: Amphetamine; Animals; Behavior, Animal; Cocaine; Dioxanes; Hyperkinesis; Male; Motor Activity; Nicot | 1998 |
Amphetamine-induced conditioned activity is insensitive to perturbations known to affect pavlovian conditioned responses in rats.
Topics: Amphetamine; Analysis of Variance; Animals; Central Nervous System Stimulants; Conditioning, Classic | 1998 |
The Ca2+ channel blockade changes the behavioral and biochemical effects of immobilization stress.
Topics: Amphetamine; Animals; Calcium Channel Blockers; Calcium Channels; Central Nervous System Stimulants; | 1999 |
The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; | 1999 |
Transgenic rescue of SNAP-25 restores dopamine-modulated synaptic transmission in the coloboma mutant.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Dopamine; Evoked Potentials; Female; Hippoc | 1999 |
GABAergic involvement in motor effects of an adenosine A(2A) receptor agonist in mice.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Amphetamine; Animals; Catalepsy; Dopamine Agents; GABA | 2000 |
The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion.
Topics: Amphetamine; Animals; Denervation; Disease Models, Animal; Dopamine; Hyperkinesis; Ibotenic Acid; Ma | 2000 |
Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania.
Topics: Amphetamine; Animals; Bipolar Disorder; Disease Models, Animal; Electromagnetic Phenomena; Hyperkine | 2001 |
Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Animals, Newborn; Behavior, Animal; Denervation; | 2001 |
Opposite effect of simple tetrahydroisoquinolines on amphetamine- and morphine-stimulated locomotor activity in mice.
Topics: Adrenergic alpha-Agonists; Amphetamine; Animals; Binding, Competitive; Brain; Calcium Channels, L-Ty | 2001 |
Augmented motor activity and reduced striatal preprodynorphin mRNA induction in response to acute amphetamine administration in metabotropic glutamate receptor 1 knockout mice.
Topics: Amphetamine; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Dose-R | 2001 |
The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Con | 2001 |
Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics.
Topics: Adrenergic alpha-Antagonists; Amphetamine; Animals; Brain; Cocaine; Dopamine; Dopamine Uptake Inhibi | 2002 |
Neurochemical investigation of an endogenous model of the "hyperkinetic syndrome" in a hybrid dog.
Topics: Adenylyl Cyclases; Amphetamine; Animals; Brain; Caudate Nucleus; Disease Models, Animal; Dogs; Dopam | 1979 |
Paradoxical effect of amphetamine in an endogenous model of the hyperkinetic syndrome in a hybrid dog: correlation with amphetamine and p-hydroxyamphetamine blood levels.
Topics: Amphetamine; Amphetamines; Animals; Behavior, Animal; Body Temperature; Dextroamphetamine; Disease M | 1979 |
Effect of lithium and other drugs on the amphetamine chlordiazeposice hyperactivity in mice.
Topics: 5-Hydroxytryptophan; Amphetamine; Animals; Bipolar Disorder; Brain Chemistry; Chlordiazepoxide; Dise | 1975 |
Possible role of 5-hydroxyptamine in minimal brain dysfunction.
Topics: Amphetamine; Animal Nutritional Physiological Phenomena; Animals; Attention Deficit Disorder with Hy | 1975 |
Amphetamine-haloperidol interactions in rat striatum: failure to correlate behavioral effects with dopaminergic and cholinergic dynamics.
Topics: Amphetamine; Animals; Behavior, Animal; Catalepsy; Choline; Corpus Striatum; Dopamine; Drug Interact | 1977 |
A dopaminergic basis for the effects of amphetamine on a mouse "preadolescent hyperkinetic" model.
Topics: Adolescent; Aging; Amphetamine; Animals; Apomorphine; Clonidine; Disease Models, Animal; Humans; Hyp | 1977 |
Behavioral changes in a juvenile primate social colony with chronic administration of d-amphetamine.
Topics: Amphetamine; Animals; Behavior, Animal; Child; Dose-Response Relationship, Drug; Haplorhini; Humans; | 1976 |
The evoked potential in pharmacopsychiatry.
Topics: Adult; Amphetamine; Antisocial Personality Disorder; Arousal; Auditory Cortex; Cerebral Cortex; Chil | 1977 |
Hyperactivity: etiology and intervention techniques.
Topics: Adaptation, Psychological; Amphetamine; Attention; Behavior Therapy; Child; Child Behavior Disorders | 1975 |
[The effect of nicotine on the concentration of noradrenaline in the brains of rats].
Topics: Amphetamine; Animals; Brain Chemistry; Depression, Chemical; Drug Interactions; Humans; Hyperkinesis | 1975 |
Letter: Amphetamine hyperactivity in rats.
Topics: Amphetamine; Animals; Humans; Hyperkinesis; Male; Rats | 1975 |
Proceedings: Pemoline in comparison with amphetamine and placebo in pedo-psychiatric practice.
Topics: Adolescent; Amphetamine; Child; Female; Humans; Hyperkinesis; Male; Pemoline | 1975 |
Ascending catecholamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non-involvement of norepinephrine.
Topics: Amphetamine; Animals; Caudate Nucleus; Cerebral Cortex; Desipramine; Dopamine; Habituation, Psychoph | 1975 |
Studies of the hyperkinetic syndrome -- Part I. An experimental analysis.
Topics: Amphetamine; Animals; Carbachol; Disease Models, Animal; Female; Humans; Hyperkinesis; Locomotion; P | 1975 |
Sequential withdrawal of stimulant drugs and use of behavior therapy with two hyperactive boys.
Topics: Amphetamine; Behavior Therapy; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate | 1976 |
Amphetamine poisoning in infant: report of two cases.
Topics: Akathisia, Drug-Induced; Amphetamine; Humans; Hyperkinesis; Hypertension; Infant; Male; Tachycardia | 1991 |
Behavioural and biochemical evidence of the interaction of the putative antipsychotic agent, BMY 14802 with the 5-HT1A receptor.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamine; Animals; Avoidance Learning; Behavior, Animal; | 1991 |
Microinjection of a glutamate antagonist into the nucleus accumbens reduces psychostimulant locomotion in rats.
Topics: Amphetamine; Analysis of Variance; Animals; Caffeine; Cocaine; Dose-Response Relationship, Drug; Exc | 1989 |
Psychopharmacologic facilitation of psychosocial therapy of violence and hyperkinesis.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Behavior, Animal; | 1988 |
Further evidence for beta-endorphin involvement in the long-lasting antagonistic effect of caerulein on amphetamine hyperactivity in rats.
Topics: Amphetamine; Animals; beta-Endorphin; Ceruletide; Dexamethasone; Endorphins; Hyperkinesis; Immune Se | 1986 |
The natural life history of children with minimal brain dysfunction.
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Cerebral Palsy; Child; Child Behavior Di | 1973 |
School problems: diagnosis and treatment.
Topics: Agnosia; Amphetamine; Anxiety; Child; Child, Preschool; Cognition Disorders; Developmental Disabilit | 1973 |
Possible antagonism of amphetamine by decongestant-antihistamine compounds.
Topics: Amphetamine; Child; Chlorpheniramine; Drug Interactions; Histamine H1 Antagonists; Humans; Hyperkine | 1974 |
The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs.
Topics: Amphetamine; Animals; Behavior; Brain; Brain Chemistry; Compulsive Behavior; Dopamine; Haloperidol; | 1970 |
Discussion of case-control study of Hodgkin's disease.
Topics: Amphetamine; Antigens, Viral; Dextroamphetamine; Epidemiologic Methods; Genotype; Herpesvirus 4, Hum | 1974 |
Hyperkineticism in children.
Topics: Amphetamine; Anticonvulsants; Child; Child Behavior Disorders; Humans; Hyperkinesis; Methylphenidate | 1970 |
The minimal brain dysfunction syndrome in children. I. The syndrome and its relevance for psychiatry. II. A psychological and biochemical model for the syndrome.
Topics: Affect; Amphetamine; Arousal; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous Syste | 1972 |
Blockade by pimozide of (+)-amphetamine-induced hyperkinesia in mice.
Topics: Amphetamine; Animals; Humans; Hyperkinesis; Injections, Intraperitoneal; Male; Mice; Motor Activity; | 1972 |
The prevention by inhibitors of brain proptein synthesis of the hyperactivity and hyperpyrexia produced in rats by monoamine oxidase inhibition and the administration of L-tryptophan or 5-methoxy-N,N-dimethyltryptamine.
Topics: Amphetamine; Animals; Brain; Carbon Isotopes; Cycloheximide; Emetine; Fever; Hallucinogens; Humans; | 1972 |
Confronting the other drug problem.
Topics: Adaptation, Psychological; Amphetamine; Behavior Therapy; Ethics, Medical; Humans; Hyperkinesis; Jur | 1972 |
Hyperactivity in children.
Topics: Amphetamine; Anticonvulsants; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; | 1973 |
Use of d-amphetamine and related central nervous system stimulants in children.
Topics: Adolescent; Amphetamine; Child; Drug and Narcotic Control; Humans; Hyperkinesis; Narcolepsy; Substan | 1973 |
The hyperactive child syndrome.
Topics: Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; C | 1973 |
The hyperactive child.
Topics: Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Di | 1973 |
[The minimal brain dysfunction syndrome].
Topics: Affective Symptoms; Amphetamine; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Chi | 1973 |
[Amphetamines in the treatment of hyperactive and instable children].
Topics: Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Hyperkinesis; Mal | 1973 |
Letter: Committee on Drugs attacked.
Topics: Amphetamine; Child; Epilepsy; Humans; Hyperkinesis | 1974 |
The case history of an infant born to an amphetamine-addicted mother.
Topics: Adult; Amphetamine; Apgar Score; Blood Glucose; Electroencephalography; Female; Fetus; Fixation, Ocu | 1974 |
Minimal brain dysfunctions in children.
Topics: Amphetamine; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Comm | 1974 |
Canine hyperkinesis.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Dogs; Humans; Hyperkinesis; Male | 1974 |
Lead-induced behavioral dysfunction: an animal model of hyperactivity.
Topics: Amphetamine; Animals; Chloral Hydrate; Dextroamphetamine; Disease Models, Animal; Female; Humans; Hy | 1974 |
Hyperactivity: a lead-induced behavior disorder.
Topics: Amphetamine; Animals; Animals, Newborn; Chloral Hydrate; Diet; Dose-Response Relationship, Drug; Fem | 1974 |
[Psychostimulant treatment of "hyperkinetic" children].
Topics: Amphetamine; Child; Humans; Hyperkinesis; Methylphenidate | 1972 |
Dissociation of learning on stimulant-drug therapy.
Topics: Amphetamine; Animals; Antidepressive Agents; Child; Dextroamphetamine; Humans; Hyperkinesis; Learnin | 1972 |
Hyperactivity in children: types, diagosis, drug therapy, approaches to management.
Topics: Amphetamine; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chroni | 1972 |
Amphetamine controls.
Topics: Amphetamine; Canada; Drug and Narcotic Control; Ethics, Medical; Humans; Hyperkinesis; Legislation, | 1972 |
Social ills and appetite pills.
Topics: Adolescent; Adult; Amphetamine; Child; Conflict, Psychological; Culture; Female; Humans; Hyperkinesi | 1971 |
Mood-altering drugs.
Topics: Amphetamine; Child; Child Behavior; Female; Humans; Hyperkinesis; Male; Methylphenidate; School Heal | 1971 |
Amphetamine effects.
Topics: Age Factors; Amphetamine; Child; Humans; Hyperkinesis; Substance-Related Disorders | 1971 |
Amphetamines in hyperkinetic children.
Topics: Amphetamine; Child; Humans; Hyperkinesis; Methylphenidate; Norepinephrine | 1971 |
A clinical view of the amphetamines.
Topics: Amphetamine; Appetite Depressants; Central Nervous System Diseases; Depression; Diazepam; Hospitaliz | 1971 |
Review of stimulant drugs in learning and behavior disorders.
Topics: Aggression; Amphetamine; Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; L | 1971 |
[Therapy of hyperactive children].
Topics: Amphetamine; Anticonvulsants; Child; Humans; Hyperkinesis; Tranquilizing Agents | 1971 |
Intracerebral lesions causing stereotyped behaviour in rats.
Topics: Amphetamine; Animals; Basal Ganglia; Behavior, Animal; Brain Injuries; Catalepsy; Catheterization; D | 1971 |
Biochemical and behavioural effect of amphetamine in DMI and Ro 4-1284 induced hyperactivity.
Topics: Amphetamine; Animals; Behavior; Desipramine; Humans; Hyperkinesis; Quinolizines; Rats | 1970 |
Paradoxical amphetamine effect in hyperactive rats in relation to norepinephrine metabolism.
Topics: Amino Acids; Amphetamine; Animals; Brain; Chlorine; Cocaine; Desipramine; Humans; Hyperkinesis; Ipro | 1970 |
Amphetamines, barbiturates, LSD and cannabis: their use and misuse.
Topics: Amphetamine; Barbiturates; Cannabis; Child Behavior Disorders; Crime; Depression; Humans; Hyperkines | 1970 |
Learning disorders, hyperkinesis, and the use of drugs in children.
Topics: Amphetamine; Child; Humans; Hyperkinesis; Learning Disabilities; Methylphenidate; Psychological Test | 1971 |
Some neuropharmacological and behavioural effects of an active fraction from Herpestis monniera, Linn (Brahmi).
Topics: Amphetamine; Animals; Body Temperature; Chlorpromazine; Drug Synergism; Humans; Hyperkinesis; Hypoth | 1967 |
On the central action of some oxoindole compounds.
Topics: Absorption; Amphetamine; Animals; Blood Pressure; Central Nervous System; Depression; Drug Antagonis | 1969 |